Early selection of an antibiotic in anaerobic infections. 1983

J C Péchère, and R Delisle

A number of antimicrobial agents are useful clinically for the treatment of anaerobic infections. Those most frequently used include the penicillins, especially penicillin G, the cephalosporins and some of their derivatives, erythromycin, clindamycin, chloramphenicol, metronidazole, and vancomycin. The present study was carried out to compare the efficacy of these antimicrobial agents based on five criteria. Antibacterial spectrum against various anaerobic organisms, of which Bacteroides fragilis is a notable representative, was the most important criterion. The bacterial resistance mechanism was our second criterion, primarily the production of enzymes of which the beta-lactamases are the prototype, as well as cell permeability alterations; although these determinations appear mostly to be a chromosomal factor, actual resistance factor plasmids have been discovered. Possible adverse effects were also carefully observed since some of these agents may cause anaphylactic shock, such as produced by the penicillins, or ulcerative colitis, which may endanger the patient's life. The pharmacokinetic profile was the fourth criterion, particularly since tissue diffusion differs so widely among these agents. Finally, the cost factor was carefully evaluated. This study concludes with a discussion relative to the principal indications of these agents for the most commonly encountered anaerobic infections seen in clinical practice.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D001922 Brain Abscess A circumscribed collection of purulent exudate in the brain, due to bacterial and other infections. The majority are caused by spread of infected material from a focus of suppuration elsewhere in the body, notably the PARANASAL SINUSES, middle ear (see EAR, MIDDLE); HEART (see also ENDOCARDITIS, BACTERIAL), and LUNG. Penetrating CRANIOCEREBRAL TRAUMA and NEUROSURGICAL PROCEDURES may also be associated with this condition. Clinical manifestations include HEADACHE; SEIZURES; focal neurologic deficits; and alterations of consciousness. (Adams et al., Principles of Neurology, 6th ed, pp712-6) Brain Abscess, Child,Brain Abscess, Multiple,Brain Abscess, Pyogenic,Brain Abscess, Sterile,Cerebral Abscess,Abscess, Brain,Abscess, Cerebral,Abscess, Child Brain,Abscess, Multiple Brain,Abscess, Pyogenic Brain,Abscesses, Cerebral,Abscesses, Multiple Brain,Brain Abscesses,Brain Abscesses, Multiple,Brain Abscesses, Pyogenic,Brain Abscesses, Sterile,Cerebral Abscesses,Child Brain Abscess,Multiple Brain Abscess,Multiple Brain Abscesses,Pyogenic Brain Abscess,Pyogenic Brain Abscesses,Sterile Brain Abscess,Sterile Brain Abscesses
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D005831 Genital Diseases, Female Pathological processes involving the female reproductive tract (GENITALIA, FEMALE). Gynecologic Diseases,Female Genital Diseases,Diseases, Female Genital,Diseases, Gynecologic,Female Genital Disease,Genital Disease, Female,Gynecologic Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000005 Abdomen That portion of the body that lies between the THORAX and the PELVIS. Abdomens
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

J C Péchère, and R Delisle
December 1976, The Journal of antimicrobial chemotherapy,
J C Péchère, and R Delisle
May 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J C Péchère, and R Delisle
August 1982, Hospital practice (Office ed.),
J C Péchère, and R Delisle
January 1989, Scandinavian journal of infectious diseases. Supplementum,
J C Péchère, and R Delisle
April 1985, American family physician,
J C Péchère, and R Delisle
August 1975, Journal of oral surgery (American Dental Association : 1965),
J C Péchère, and R Delisle
January 1979, Annali dell'Istituto superiore di sanita,
J C Péchère, and R Delisle
April 1960, Postgraduate medicine,
J C Péchère, and R Delisle
November 1995, The Journal of the Greater Houston Dental Society,
J C Péchère, and R Delisle
November 2019, Iranian journal of public health,
Copied contents to your clipboard!